Thomas Force
-
- Cardiac Fibrosis and Remodeling 27
- Chemotherapy-induced cardiotoxicity and mitigation 23
- Cardiac electrophysiology and arrhythmias 20
- Molecular Biology top 0.5%
- Signaling Pathways in Disease 23
- Protein Kinase Regulation and GTPase Signaling 16
- Melanoma and MAPK Pathways 14
- Wnt/β-catenin signaling in development and cancer 14
- PI3K/AKT/mTOR signaling in cancer 12
- Oncology top 0.5%
- Hematology top 1%
- Pathology and Forensic Medicine top 0.5%
- Co-authors
- Joseph V. BonventreRisto KerkeläJohn KyriakisJames R. WoodgettRichard A. Van EttenGerald W. DornAnthony RosenzweigRoger J. Hajjar
- Journals
- Circulation (19 papers)Journal of Biological Chemistry (17 papers)Circulation Research (14 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Thomas Force
158 papers receiving 16.5k citations
Hit Papers
Peers
Comparison fields: 5 of 158
- Cardiology and Cardiovascular Medicine 6.5k
- Molecular Biology 8.9k
- Oncology 3.2k
- Hematology 900
- Pathology and Forensic Medicine 1.4k
Countries citing papers authored by Thomas Force
This map shows the geographic impact of Thomas Force's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Force with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Force more than expected).
Fields of papers citing papers by Thomas Force
This network shows the impact of papers produced by Thomas Force. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Force. The network helps show where Thomas Force may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Thomas Force, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 31 | |
| 2 | 2014 | 146 | |
| 3 | TNNI3K, a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease | 2014 | 2 |
| 4 | 2014 | 14 | |
| 5 | 2013 | 47 | |
| 6 | 2012 | 4 | |
| 7 | 2011 | 278 | |
| 8 | 2010 | 98 | |
| 9 | 2010 | 2 | |
| 10 | 2008 | 43 | |
| 11 | 2007 | 40 | |
| 12 | 2006 | 44 | |
| 13 | 2006 | 84 | |
| 14 | Cardiotoxicity of the cancer therapeutic agent imatinib mesylatebreakdown → | 2006 | 858 |
| 15 | 2005 | 106 | |
| 16 | 2005 | 3 | |
| 17 | 2004 | 190 | |
| 18 | 2004 | 1 | |
| 19 | 2000 | 42 | |
| 20 | 1997 | 39 |
About Thomas Force
Thomas Force is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Hematology, having authored 158 papers that have together received 16.8k indexed citations. Recurring topics across this work include Cardiac Fibrosis and Remodeling (27 papers), Signaling Pathways in Disease (23 papers), Chemotherapy-induced cardiotoxicity and mitigation (23 papers), Cardiac electrophysiology and arrhythmias (20 papers), Protein Kinase Regulation and GTPase Signaling (16 papers), Melanoma and MAPK Pathways (14 papers), Wnt/β-catenin signaling in development and cancer (14 papers) and PI3K/AKT/mTOR signaling in cancer (12 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (6.5k citations), Molecular Biology (8.9k citations) and Oncology (3.2k citations). Thomas Force has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Joseph V. Bonventre, Risto Kerkelä, John Kyriakis, James R. Woodgett, Richard A. Van Etten, Gerald W. Dorn, Anthony Rosenzweig, Roger J. Hajjar, Syed Haq and Daniela S. Krause. Their work appears in journals such as Circulation, Journal of Biological Chemistry, Circulation Research, Molecular and Cellular Biology and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.